A phase II exploratory, randomized, placebo-controlled trial of pomegranate fruit extract (PFE)/pomx in subjects with clinically localized prostate cancer undergoing active surveillance…
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
University Of Wisconsin System UEI LCLSJAGTNZQ7 Part of University Of Wisconsin System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $572,545
Award facts
- Opportunity
-
- TORFPK Solicitation number
- Contract value 100% obligated
- $572,545.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Madison, WI 53715, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $2,934 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Funding Only Action | -$3,573 | |
| Exercise an Option | $84,941 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $488,243 |
About this award
The National Cancer Institute issued a delivery order to the University of Wisconsin System on September 24, 2013, with a ceiling value of $572,545.00 under the Cancer Prevention Agent Development Program 2012-2017 for a Phase II exploratory, randomized, placebo-controlled trial of pomegranate fruit extract in subjects with clinically localized prostate cancer undergoing active surveillance.
Place of performance is Madison, Wisconsin. The order ultimate completion date is September 23, 2019. Pricing is cost no fee.
Description
A phase II exploratory, randomized, placebo-controlled trial of pomegranate fruit extract (PFE)/pomx in subjects with clinically localized prostate cancer undergoing active surveillance (UWI2013-00-01)
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to University Of Wisconsin System by National Cancer Institute (National Institutes of Health) on September 24, 2013.
How much is contract HHSN26100003 worth?
The government has obligated $572,545 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201200033I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award